Agreement - June 25, 2014
Oasmia in research agreement
Swedish pharmaceutical company Oasmia Pharmaceutical AB has announced that a research agreement has been signed between Oasmia and a global pharmaceutical company. The agreement relates to the use of Oasmia’s patented nanoparticle formulation technology XR-17. The full terms of the agreement have not been disclosed at this point in time. Oasmia will initially perform tests to […]
Uncategorized - June 24, 2014
Medtronic announces preliminary outcomes for world’s smallest cardiac pacemaker
Results from the first four patients to receive the Micra TPS were reported at CARDIOSTIM / EHRA EUROPACE 2014, World Congress in Electrophysiology and Cardiac Techniques, in Nice, France. At 1 month and 3 months, results showed the Micra TPS was successfully implanted in all patients, whose ages ranged from 74 to 83 years, and […]
Agreement - June 24, 2014
Aurigene and Orion Corporation collaborate
Finnish pharmaceuticals company Orion Corporation and Indian biotech company Aurigene have entered into an option and research & collaboration agreement. The agreement regards rights to Aurigene’s Pan BET and Selective BET Bromodomain inhibitors program. Under the terms of the option agreement, Aurigene will receive an upfront payment from Orion, followed by a licensing fee, milestones and royalties upon exercising the option at the Candidate […]
MedTech Business - June 24, 2014
CellaVision acquires new technology platform
The platform was acquired from US high technology company Clear Lake Medical Foundation, and will be the foundation of a future development project. According to CellaVision, the new technology has the potential to develop into an affordable solution for the smaller hospital laboratories. The purchase price payable in installments upon achievement of certain goals will […]
Uncategorized - June 23, 2014
Norway invests NOK 850 million in innovation projects
The Norwegian Research Council will grant NOK 850 million to industry innovation projects, which is the largest grant of its kind in history. In 2013, the grant to innovation projects within the industry was on 700 million. The increase on 150 MNOK mainly comes from the Government’s strenghtening of the Research Council’s BIA program, a program […]
Clinical Trials - June 23, 2014
Orexo reports positive results from phase III trials
The company has announced the results of two phase III clinical trials assessing Zubsolv for induction of buprenorphine maintenance therapy in patients with opioid dependence. Combined data from the Induction, STabilization, Adherence and Retention Trial (ISTART) (Study OX219-006) and Study OX219-007, in 1068 opioid dependent patients, showed that over 90% of patients treated with Zubsolv […]
